Stockscreener 앱 받기
27.57
2.80%
0.75
전일 마감가:
$26.82
열려 있는:
$26.87
하루 거래량:
835.52K
Relative Volume:
0.47
시가총액:
$1.74B
수익:
$18.09M
순이익/손실:
$-208.87M
주가수익비율:
-7.8491
EPS:
-3.5125
순현금흐름:
$-178.15M
1주 성능:
+4.23%
1개월 성능:
-5.26%
6개월 성능:
+41.31%
1년 성능:
+72.42%
1일 변동 폭
$26.80
$28.71
1주일 범위
$25.65
$28.71
52주 변동 폭
$8.73
$71.50
Uniqure Nv Stock (QURE) Company Profile
명칭
Uniqure Nv
전화
1-339-970-7000
주소
PAASHEUVELWEG 25A, AMSTERDAM
Compare QURE vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
QURE
Uniqure Nv
|
27.57 | 1.74B | 18.09M | -208.87M | -178.15M | -3.5125 |
VRTX
Vertex Pharmaceuticals Inc
|
444.93 | 112.92B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
612.14 | 64.18B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
893.52 | 55.57B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.85 | 37.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.87 | 32.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
Uniqure Nv Stock (QURE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-11 | 업그레이드 | Mizuho | Neutral → Outperform |
| 2026-03-09 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2026-03-09 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2026-03-03 | 다운그레이드 | Mizuho | Outperform → Neutral |
| 2026-03-03 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2026-03-02 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2026-03-02 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2026-02-24 | 개시 | Wolfe Research | Peer Perform |
| 2026-01-28 | 개시 | Barclays | Equal Weight |
| 2025-11-04 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2025-08-14 | 업그레이드 | Mizuho | Neutral → Outperform |
| 2025-04-01 | 재개 | Chardan Capital Markets | Buy |
| 2024-12-10 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-02-29 | 다운그레이드 | Goldman | Buy → Neutral |
| 2023-12-19 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2022-03-17 | 업그레이드 | UBS | Neutral → Buy |
| 2021-06-15 | 개시 | BTIG Research | Buy |
| 2021-05-21 | 개시 | UBS | Neutral |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-04-01 | 업그레이드 | Mizuho | Neutral → Buy |
| 2021-01-07 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-11-24 | 개시 | H.C. Wainwright | Buy |
| 2020-11-11 | 개시 | Berenberg | Buy |
| 2020-11-09 | 개시 | Jefferies | Buy |
| 2020-11-04 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-10-23 | 개시 | RBC Capital Mkts | Outperform |
| 2020-08-25 | 개시 | Raymond James | Strong Buy |
| 2020-07-31 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2020-06-25 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2020-06-25 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2020-06-25 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2019-12-03 | 개시 | Cowen | Outperform |
| 2019-12-03 | 개시 | Goldman | Buy |
| 2019-11-05 | 개시 | Credit Suisse | Outperform |
| 2019-10-11 | 개시 | Stifel | Buy |
| 2019-09-25 | 개시 | Bernstein | Outperform |
| 2019-09-12 | 개시 | Mizuho | Buy |
| 2019-07-30 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-07-08 | 재확인 | Cantor Fitzgerald | Overweight |
| 2019-04-12 | 개시 | Piper Jaffray | Overweight |
| 2019-03-29 | 개시 | Robert W. Baird | Outperform |
모두보기
Uniqure Nv 주식(QURE)의 최신 뉴스
RSU grant, options and tax sale for uniQure (NASDAQ: QURE) director - Stock Titan
uniQure (QURE) director trades shares, receives RSUs and stock options - Stock Titan
Tax-related share sale by uniQure (NASDAQ: QURE) chief customer officer - Stock Titan
uniQure (QURE) director receives RSUs, stock options and sells shares for taxes - Stock Titan
uniQure (QURE) director Leonard Post awarded RSUs, options and sells shares for taxes - Stock Titan
Director Jack Kaye at uniQure (QURE) gets RSUs and options, sells shares for taxes - Stock Titan
Equity awards and tax-driven share sale for uniQure (NASDAQ: QURE) director - Stock Titan
uniQure (NASDAQ: QURE) director awarded RSUs, sells shares for taxes - Stock Titan
What Caused uniQure's Dramatic Stock Plunge - Kavout
[144] uniQure N.V. SEC Filing - Stock Titan
UniQure (NASDAQ: QURE) reports 7,970 RSUs vest and 10,000-share 10b5-1 sale - Stock Titan
UniQure N.V. (QURE) files Rule 144 to sell 7,970 RSU shares on 06/11/2026 - Stock Titan
Jack Kaye sale notice at UniQure (NASDAQ: QURE) — 7,970 shares proposed - Stock Titan
QURE Stock Just Shot Up 8%uniQure’s Much-Talked-About Huntington’s Disease Therapy Gets A UK Boost - Stocktwits
Trading the Move, Not the Narrative: (QURE) Edition - Stock Traders Daily
Fiera Capital Corp Invests $18.39 Million in uniQure N.V. $QURE - MarketBeat
Why Did QURE Stock Almost Halve Pre-Market Today? - Stocktwits
QURE Jumps 20% – Analysts Upgrade Stock On Huntington’s Disease Therapy Update, Retail Eyes $150 - Stocktwits
What Just Happened with uniQure's Earnings and FDA Update - Kavout
QURE Q1 2026 Earnings: Narrower-Than-Expected Loss Fails to Lift SharesWeak Earnings Momentum - newsline.com
Director Kaye trades uniQure (QURE) shares in 10b5-1 option exercise and sale - Stock Titan
Huntingtons Disease Market Size to Hit USD 6.48 Billion by 2035 - Precedence Research
Mizuho downgrades UniQure NV (QURE) - MSN
Form 144 uniQure N.V. For: 3 June By Investing.com - Investing.com South Africa
uniQure: Why A Shifting FDA Could Change Everything For AMT-130 (NASDAQ:QURE) - Seeking Alpha
Tracing UniQure's Tale Of Boom, Bust, And Rebound - RTTNews
(QURE) Volatility Zones as Tactical Triggers - Stock Traders Daily
uniQure stock surges 20% on Replimune FDA BLA news By Investing.com - Investing.com Australia
uniQure stock surges 20% on Replimune FDA BLA news - Investing.com
QURE News | UNIQURE NV (NASDAQ:QURE) - ChartMill
uniQure N.V. stock (IL0011559904): Gene therapy player navigates strategic reset and cash conservati - AD HOC NEWS
uniQure Q1 2026 Earnings: Narrower-Than-Expected Loss Amid No Revenue, Stock SlipsCapex Guidance - newsline.com
Numero AI and Royu Merge to Redefine How Finance Teams Operate - Benzinga
UniQure stock falls after FDA's notes on pre-application of AMT-130 - MSN
Considering Uniqure NV (QURE) Stock? Read the AMT-130 Message - Insider Monkey
Uniqure NV at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
uniQure N.V. (QURE) Stalls at $24.84 — Breakout or Breakdown? 2026-05-19PCR Moving Average - newsline.com
Price-Driven Insight from (QURE) for Rule-Based Strategy - Stock Traders Daily
Huntington's Disease Pipeline 2026: Therapies Under - openPR.com
UniQure NV (QURE) price target decreased by 26.57% to 37.82 - MSN
Mizuho maintains uniQure NV (QURE) outperform recommendation - MSN
QURE stock just shot up 8%uniQure’s much-talked-about Huntington’s disease therapy gets a UK boost - MSN
UBS Group AG Buys 286,465 Shares of uniQure N.V. $QURE - MarketBeat
Uniqure Nv (QURE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Uniqure Nv 주식 (QURE) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Gut Robert | Director |
Jun 10 '26 |
Option Exercise |
16.04 |
2,645 |
42,426 |
34,987 |
| Gut Robert | Director |
Jun 10 '26 |
Sale |
26.05 |
7,552 |
196,720 |
27,435 |
| Gut Robert | Director |
Jun 11 '26 |
Sale |
27.06 |
2,726 |
73,766 |
32,259 |
| O'Keefe Kylie | Chief Customer & Strat Officer |
Jun 11 '26 |
Sale |
27.06 |
15,936 |
431,228 |
108,864 |
| Springhorn Jeremy P. | Director |
Jun 11 '26 |
Sale |
27.06 |
1,993 |
53,931 |
43,251 |
| POST LEONARD E | Director |
Jun 11 '26 |
Sale |
27.06 |
1,993 |
53,931 |
35,494 |
| Kaye Jack | Director |
Jun 11 '26 |
Sale |
27.06 |
1,993 |
53,931 |
25,996 |
| Jacques Rachelle Suzanne | Director |
Jun 11 '26 |
Sale |
27.06 |
1,993 |
53,931 |
33,903 |
| Balachandran Madhavan | Director |
Jun 11 '26 |
Sale |
27.06 |
1,993 |
53,931 |
43,254 |
1.04%
0.76%
자본화:
|
볼륨(24시간):